Gaithersburg, Maryland-based Novavax, whose experimental COVID-19 vaccine is now in limited human trials, has acquired Praha Vaccines A.S., gaining its biologics manufacturing facility in Bohumil, Czech Republic, for USD 167 million.
Gaithersburg, Maryland-based Novavax, whose experimental COVID-19 vaccine is now in limited human trials, has acquired Praha Vaccines A.S., gaining its biologics manufacturing facility in Bohumil, Czech Republic, for USD 167 million.
most viewed
© 2023 The Prague Monitor